China’s Personalized Cancer Vaccine Pipeline: Who Is Actually in the Clinic?

Personalized cancer vaccines are becoming one of the most active areas in China’s mRNA and neoantigen ecosystem. A growing number of companies and hospitals are using tumor sequencing, neoantigen prediction, and individualized manufacturing to develop vaccines tailored to each patient.

However, the landscape is more complicated than the number of announced programs suggests.

Some programs are true personalized cancer vaccines, or PCVs, in which the vaccine is manufactured using neoantigens selected specifically for an individual patient. Others are off-the-shelf vaccines targeting shared mutations, viral antigens, or tumor-associated antigens. Several additional programs use similar technologies but are better classified as TCR-T, neoantigen-specific T-cell therapy, in vivo CAR-T, or cytokine-encoding mRNA.

The first version of the Inside China Biotech PCV database therefore focuses not only on who is developing cancer vaccines, but also on what kind of product each program actually represents.

The leading personalized programs

A relatively small group of companies currently has the most visible patient-specific PCV programs.

Likang Life’s LK101 is one of the more advanced examples. It is a personalized neoantigen mRNA–dendritic-cell vaccine, with an NMPA IND granted in 2023 and an FDA IND approved in 2025. The program has been associated with advanced solid tumors, including lung cancer, melanoma, and hepatocellular carcinoma. Unlike an mRNA-LNP vaccine injected directly into the patient, LK101 uses patient-derived dendritic cells as the delivery and antigen-presentation platform.

Everest Medicines’ EVM16 represents a more conventional personalized mRNA-LNP approach. The program uses the company’s EVER-NEO-1 neoantigen prediction platform to select patient-specific targets, which are then encoded into an mRNA vaccine. Early first-in-human data have been reported in advanced solid tumors, including gastroesophageal junction cancer, non-small-cell lung cancer, and esophageal squamous-cell carcinoma.

Abogen’s ABO2109, Rhegen Bio’s RH125, and Xinpu Bio’s XP-004 and XP-006 further illustrate the growing depth of the domestic pipeline. These programs span advanced solid tumors, postoperative adjuvant settings, pancreatic cancer, and relapsed or refractory B-cell lymphoma. Most remain in Phase I or IIT-stage development, and public efficacy datasets are still limited.

China’s PCV field is still largely IIT-driven

One of the most important characteristics of the Chinese PCV ecosystem is the role of investigator-initiated trials.

IITs allow companies to generate early human data, test vaccine manufacturing workflows, evaluate immune responses, and establish relationships with leading investigators before entering a formal company-sponsored IND program. This is particularly useful for personalized vaccines, where sequencing, bioinformatics, manufacturing, and treatment must all be coordinated within a relatively short time window.

But IIT status should not be confused with late-stage clinical validation.

Many of the reported datasets are small, single-center, non-randomized, or company-reported. Some include promising response rates or immune signals, but the evidence is not yet comparable with mature randomized studies. The database therefore separates trial registration, company-reported human data, peer-reviewed evidence, and formal IND-stage development wherever possible.

Personalized does not mean the same thing across the pipeline

Another challenge is classification.

A true PCV is designed around neoantigens identified from an individual patient’s tumor. By contrast:

• EVM14 (Everest Medicines) is an off-the-shelf vaccine encoding five tumor-associated antigens.

• ABO2102 (Abogen Bioscience) targets common KRAS mutations.

• ABO2013 (Abogen Bioscience) targets shared EGFR mutations.

• ABOR2014/IPM511 (Abogen Bioscience) encodes frequently observed hepatocellular carcinoma antigens.

• WGc-043 (WestGene Biopharma) targets EBV-associated cancers.

• AFN0328 (Ankebio) targets HPV16/18-related disease.

These are important therapeutic cancer vaccine programs, but they are not strictly personalized vaccines.

The same distinction applies to adjacent technologies. Immorna Biotherapeutics ’s JCXH-211 is an mRNA-encoded IL-12 program, while JCXH-213 is an mRNA-LNP in vivo CAR-T therapy. Rhegen Bio’s RH130 is an mRNA-encoded T-cell engager. Likang is also developing neoantigen-specific T-cell and TCR-T platforms. These programs are relevant to the broader RNA and neoantigen ecosystem.

Three patterns are beginning to emerge

1. mRNA is becoming the dominant development format

China’s earlier personalized vaccine activity included peptide and dendritic-cell approaches, but most newer programs are moving toward mRNA. The attraction is clear: multiple neoantigens can be encoded in one construct, manufacturing can be standardized, and the same platform can be reused across patients.

The unresolved question is whether China’s developers can build manufacturing systems that are fast, reproducible, and economical enough for routine clinical use.

2. Postoperative adjuvant settings may become strategically important

Several Chinese programs are moving beyond heavily pretreated metastatic disease and into postoperative settings, including pancreatic cancer, liver cancer, and other high-risk solid tumors.

This may be a more suitable setting for PCVs because tumor burden is lower, immune function may be better preserved, and the vaccine can potentially eliminate microscopic residual disease before recurrence becomes clinically visible.

3. The field is moving from platforms toward evidence

Many companies initially emphasized AI neoantigen prediction, proprietary delivery systems, or manufacturing platforms. The next stage will depend less on how sophisticated the platform sounds and more on whether developers can show:

• consistent vaccine manufacturing timelines;

• reliable CD4 and CD8 T-cell responses;

• clinically meaningful recurrence or survival benefits;

• reproducibility across hospitals and patient populations;

• and a feasible path to commercial-scale production.

What the database will track

The Inside China Biotech PCV database will continue to distinguish programs by:

• personalized versus off-the-shelf design;

• mRNA, peptide, or dendritic-cell modality;

• IIT versus formal IND-stage development;

• availability and quality of human data;

• tumor indication;

• clinical-trial evidence;

• and the maturity of manufacturing and commercialization.

The purpose is to understand which programs represent genuine clinical progress, which are still platform concepts, and which may become globally relevant assets.

China’s PCV ecosystem is no longer empty or purely exploratory. But it is also not yet a mature, validated market. The next few years will show which companies can move from early IIT signals and platform narratives to reproducible clinical outcomes.